MARC record from Internet Archive

LEADER: 04353cam 2200817 a 4500
001 ocm38324279
003 OCoLC
005 20200528024247.0
008 980126s1998 nyu b 001 0 eng
010 $a 98004689
040 $aDLC$beng$cDLC$dCOU$dNLM$dBAKER$dBTCTA$dYDXCP$dGEBAY$dEXW$dX2#$dBDX$dOCLCO$dCSJ$dOCLCO$dOCLCQ$dOCLCA$dOCLCF$dOCLCA$dPAU$dBGU$dOCLCO$dCNO$dEUQ$dOCLCA$dOCLCQ
016 7 $a9816884$2DNLM
019 $a1064710152$a1077833133$a1084282223$a1084922999
020 $a0789005638$q(hard ;$qalk. paper)
020 $a9780789005632$q(hard ;$qalk. paper)
020 $a0789005646
020 $a9780789005649
035 $a(OCoLC)38324279$z(OCoLC)1064710152$z(OCoLC)1077833133$z(OCoLC)1084282223$z(OCoLC)1084922999
050 00 $aR726.8$b.S37 1998
060 00 $a1998 J-562
060 10 $aWB 310$bS385a 1998
082 00 $a174/.28$221
100 1 $aSchüklenk, Udo.
245 10 $aAccess to experimental drugs in terminal illness :$bethical issues /$cUdo Schüklenk.
260 $aNew York :$bPharmaceutical Products Press,$c1998.
300 $ax, 228 pages ;$c23 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references (pages 205-217) and index.
505 00 $tAutonomy--Access to Experimental Drugs and the Terminally Ill --$tImmanuel Kant --$tWeak Paternalism: John Stuart Mill --$tWeak Paternalism: Joel Feinberg --$tWeak Paternalism: Gerald Dworkin --$tWeak Paternalism: Tom L. Beauchamp, James F. Childress, and Ruth R. Faden --$tStrong Paternalism: Robert Young --$tThe Importance of Respecting Individual Autonomy --$tSummary of the Philosophical Debate --$tPractical Implications of the Arguments --$tShould We Restrict Access to Experimental Drugs to Promote Clinical Trials? --$tResearch Clinical Trials--Are They Designed to Help Current or Future Patients? --$tPhysicians and Patients --$tThe Fischl/Richman AZT Trial --$tEthical Analysis of the Fischl/Richman AZT Trial --$tCoercive Offers, or You Cannot Have It Both Ways --$tPlacebos and Other Drugs --$tCosts and Other Practical Problems --$tAccess to Experimental Drugs in Societies with Universal Health Care --$tAccess to Experimental Drugs in Societies Without Universal Health Care --$tProvision of Information About Experimental Drugs --$tPractical Cultural Hindrances in Exercising Autonomy.
650 0 $aTerminal care$xMoral and ethical aspects.
650 0 $aDrugs$xTesting$xMoral and ethical aspects.
650 0 $aHealth services accessibility.
650 0 $aDrug accessibility$xMoral and ethical aspects.
650 12 $aTerminal Care.
650 22 $aDrug Approval.
650 22 $aDrugs, Investigational$xtherapeutic use.
650 22 $aEthics, Medical.
650 7 $aDrugs$xTesting$xMoral and ethical aspects.$2fast$0(OCoLC)fst00898948
650 7 $aHealth services accessibility.$2fast$0(OCoLC)fst00953278
650 7 $aTerminal care$xMoral and ethical aspects.$2fast$0(OCoLC)fst01147846
650 7 $aUnheilbarkeit$2gnd
650 7 $aKlinische Prüfung$2gnd
650 7 $aEthik$2gnd
650 7 $aAufsatzsammlung$2gnd
650 7 $aLebensbedrohende Krankheit$2gnd
650 7 $aArzneiverordnung$2gnd
650 7 $aArzneimittelsicherheit$2gnd
650 07 $aUnheilbarkeit.$2swd
650 07 $aKlinische Prüfung.$2swd
650 07 $aEthik.$2swd
650 07 $aAufsatzsammlung.$2swd
650 07 $aLebensbedrohende Krankheit.$2swd
650 07 $aArzneiverordnung.$2swd
650 07 $aArzneimittelsicherheit.$2swd
776 08 $iOnline version:$aSchüklenk, Udo.$tAccess to experimental drugs in terminal illness.$dNew York : Pharmaceutical Products Press, 1998$w(OCoLC)607126061
856 42 $3The Samuel Bellet Book Fund Home Page$uhttp://hdl.library.upenn.edu/1017.12/366191
938 $aBaker & Taylor$bBKTY$c59.95$d59.95$i0789005638$n0003159859$sactive
938 $aBrodart$bBROD$n53715896$c$74.95
938 $aBaker and Taylor$bBTCP$n98004689
938 $aYBP Library Services$bYANK$n1499492
029 1 $aAU@$b000013698758
029 1 $aGEBAY$b5803511
029 1 $aHEBIS$b10333078X
029 1 $aNLGGC$b167239686
029 1 $aNLM$b9816884
029 1 $aNZ1$b2276601
029 1 $aYDXCP$b1499492
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 233 OTHER HOLDINGS